International Scholarly Research Notices

Clinical Study

The Incidence of Various Antiphospholipid Antibodies, Measured by Commercial-Based Laboratory, with Recurrent Spontenous Abortion and the Impact of Their Profiles on Reproductive Outcome with Active Anticoagulant Therapy

Table 1

Incidence of various aPL profiles in RSA patients without possible causes.
aPL type and titeraPL typeaPL titer
Positive/tested (positive rate; %)Positive/tested (positive rate; %)
LA
 weakly47/263 (17.9%)45/263 (17.1%)
 strongly2/263 (0.8%)
aβ2GPI
 weakly1/263 (0.4%)1/263 (0.4%)
 strongly0/263 (0%)
aCL-IgG
 weakly23/263 (8.7%)12/263 (4.6%)
 strongly11/263 (4.2%)
-IgM
 weakly71/263 (27.0%)50/263 (19.0%)
 strongly21/263 (8.0%)
aPE-IgG
 weakly31/263 (11.8%)22/263 (8.4%)
 strongly9/263 (3.4%)
-IgM
 weakly31/263 (11.8%)23/263 (8.7%)
 strongly8/263 (3.0%)
aPS-IgG
 weakly17/263 (6.5%)12/263 (4.6%)
 strongly5/263 (1.9%)
-IgM
 weakly73/263 (27.8%)51/263 (19.4%)
 strongly22/263 (8.4%)
Positive titers of aPLs were defined as follows:
LA: weakly; from 1.12 to 1.30, strongly; over 1.30.
aβ2GPI: weakly; from 1.9 to 3.5 U/mL, strongly; over 3.5 U/mL.
aCL-IgG: weakly; from 10 to 20 U/mL, strongly; over 20 U/mL.
aCL-IgM: weakly; from 1.0 to 2.0 U/mL, strongly; over 2.0 U/mL.
aPE-IgG: weakly; from 0.3 to 0.5 U/mL, strongly; over 0.5 U/mL.
aPE-IgM: weakly; from 0.45 to 0.75 U/mL, strongly; over 0.75 U/mL.
aPS-IgG: weakly; from 1.0 to 1.66 U/mL, strongly; over 1.66 U/mL.
aPS-IgM: weakly; from 1.0 to 1.66 U/mL, strongly; over 1.66 U/mL.